Trial Profile
A Multi-Center Cardiac Safety Study of Subjects Who Participated in Organon Sponsored Phase 1 and Phase 2 Completed and Discontinued Trials With Org 24448
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Farampator (Primary)
- Indications Psychotic disorders
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Organon
- 18 Feb 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 18 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Nov 2008 New trial record.